GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » ClouDr Group Ltd (HKSE:09955) » Definitions » 3-Year RORE %

ClouDr Group (HKSE:09955) 3-Year RORE % : -63.83% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is ClouDr Group 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. ClouDr Group's 3-Year RORE % for the quarter that ended in Dec. 2023 was -63.83%.

The industry rank for ClouDr Group's 3-Year RORE % or its related term are showing as below:

HKSE:09955's 3-Year RORE % is ranked worse than
86.21% of 87 companies
in the Medical Distribution industry
Industry Median: -1.1 vs HKSE:09955: -63.83

ClouDr Group 3-Year RORE % Historical Data

The historical data trend for ClouDr Group's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClouDr Group 3-Year RORE % Chart

ClouDr Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
- - 48.95 - -63.83

ClouDr Group Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
3-Year RORE % Get a 7-Day Free Trial 48.95 - - - -63.83

Competitive Comparison of ClouDr Group's 3-Year RORE %

For the Medical Distribution subindustry, ClouDr Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClouDr Group's 3-Year RORE % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, ClouDr Group's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where ClouDr Group's 3-Year RORE % falls into.



ClouDr Group 3-Year RORE % Calculation

ClouDr Group's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.656--8.849 )/( -12.835-0 )
=8.193/-12.835
=-63.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.


ClouDr Group  (HKSE:09955) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


ClouDr Group 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of ClouDr Group's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


ClouDr Group (HKSE:09955) Business Description

Traded in Other Exchanges
Address
No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
Executives
Trident Trust Company (hk) Limited 2301 Trustee
Data Vantage Development Limited 2201 Interest of corporation controlled by you
Kuang Ming 2201 Interest of corporation controlled by you
Prime Forest Assets Limited 2101 Beneficial owner
Shang Hai Qi Ji Ke Ji He Huo Qi Ye You Xian He Huo
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Zhao Yin Guo Ji Jin Rong You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Ho Chi Sing 2201 Interest of corporation controlled by you
China Merchants Bank Co., Ltd.
Zhou Quan 2201 Interest of corporation controlled by you
Idg China Venture Capital Fund Gp Iv Associates Ltd. 2201 Interest of corporation controlled by you
Haoyuan Health Limited 2101 Beneficial owner
Yass Jeffrey Steven

ClouDr Group (HKSE:09955) Headlines

No Headlines